rofecoxib has been researched along with Cholera Infantum in 78 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 9.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 9.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market." | 7.78 | Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012) |
| "We used decision analysis to compare the life expectancy of a cohort of rheumatoid arthritis patients taking naproxen versus a similar cohort taking rofecoxib, using data from the VIGOR trial." | 7.72 | Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 5.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 5.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| "Eight thousand seventy-six rheumatoid arthritis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months." | 5.10 | Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. ( Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D, 2002) |
| "A total of 8076 rheumatoid arthritis patients 50 years or older (or 40 years or older on corticosteroid therapy) expected to require NSAIDs for 1 year or greater were randomly assigned to naproxen 500 mg twice daily or rofecoxib 50 mg daily." | 5.10 | Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. ( Bombardier, C; Burgos-Vargas, R; Connors, LG; Hawkey, CJ; Laine, L; Reicin, A; Schnitzer, TJ; Yu, Q, 2003) |
| "To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| " We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis." | 5.09 | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000) |
| "To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market." | 3.78 | Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012) |
| "During the review process of the Vioxx Gastrointestinal Outcomes Research study, it was suggested that rofecoxib might have little benefit, with regard to GI toxicity, for patients with rheumatoid arthritis not treated with corticosteroids." | 3.77 | Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. ( Chan, FK; Graham, DY; Jewell, NP, 2011) |
| "This study was designed to assess the cost-effectiveness of cyclooxygenase-2 specific (COX-2) inhibitors (rofecoxib and celecoxib) over nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in high-risk arthritis patients from the perspective of the Veterans Health Administration (VA)." | 3.73 | Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. ( Botteman, M; DeLattre, M; Gao, X; Morreale, A; Schaefer, M; Stephens, J, 2005) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| "We used decision analysis to compare the life expectancy of a cohort of rheumatoid arthritis patients taking naproxen versus a similar cohort taking rofecoxib, using data from the VIGOR trial." | 3.72 | Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib." | 3.71 | Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002) |
| " This article critically reviews the data on gastrointestinal toxic side effects for conventional NSAIDs without as well as with prevention therapy." | 2.41 | Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. ( Burmester, GR; Buttgereit, F; Simon, LS, 2001) |
| " Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy." | 2.41 | Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002) |
| " A dose-response relationship was observed for rofecoxib and naproxen with ORs for high dose of 5." | 1.35 | Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. ( Castellsague, J; Gimeno, V; Hoffman, CC; Holick, CN; Perez-Gutthann, S; Stang, MR, 2009) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 1.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| " Chronic administration of NSAIDs at the ED(50) doses (nimesulide, rofecoxib and naproxen for 15 days) significantly reversed the age or scopolamine-induced retention deficits in both test paradigms." | 1.31 | Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. ( Jain, NK; Kulkarni, SK; Patil, CS; Singh, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 74 (94.87) | 29.6817 |
| 2010's | 4 (5.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Setakis, E | 1 |
| Leufkens, HG | 3 |
| van Staa, TP | 2 |
| Hill, KP | 1 |
| Ross, JS | 1 |
| Egilman, DS | 1 |
| Krumholz, HM | 1 |
| Jackson, G | 1 |
| Castellsague, J | 1 |
| Holick, CN | 1 |
| Hoffman, CC | 1 |
| Gimeno, V | 1 |
| Stang, MR | 1 |
| Perez-Gutthann, S | 1 |
| Graham, DY | 1 |
| Jewell, NP | 1 |
| Chan, FK | 1 |
| Bombardier, C | 6 |
| Laine, L | 5 |
| Day, R | 3 |
| Hawkey, CJ | 7 |
| Hochberg, MC | 3 |
| Schnitzer, TJ | 4 |
| Marra, CA | 1 |
| Lynd, LD | 1 |
| Colley, L | 1 |
| Harvard, SS | 1 |
| Lacaille, D | 1 |
| Schwenger, E | 1 |
| Anis, AH | 1 |
| Esdaile, JM | 1 |
| Valkhoff, VE | 1 |
| van Soest, EM | 1 |
| Masclee, GM | 1 |
| de Bie, S | 1 |
| Mazzaglia, G | 1 |
| Molokhia, M | 1 |
| Kuipers, EJ | 1 |
| Sturkenboom, MC | 1 |
| Jain, NK | 1 |
| Patil, CS | 1 |
| Kulkarni, SK | 1 |
| Singh, A | 1 |
| Budenholzer, BR | 1 |
| Steinfeld, S | 1 |
| Bjørke, PA | 1 |
| Davis, B | 3 |
| Shapiro, D | 3 |
| Brett, C | 1 |
| Reicin, A | 4 |
| Connors, LG | 1 |
| Burgos-Vargas, R | 3 |
| Yu, Q | 1 |
| Micklewright, R | 1 |
| Lane, S | 1 |
| Linley, W | 1 |
| McQuade, C | 1 |
| Thompson, F | 1 |
| Maskrey, N | 1 |
| Layton, D | 2 |
| Heeley, E | 1 |
| Hughes, K | 1 |
| Shakir, SA | 2 |
| Maetzel, A | 1 |
| Krahn, M | 1 |
| Naglie, G | 1 |
| James, MW | 1 |
| Verrico, MM | 1 |
| Weber, RJ | 1 |
| McKaveney, TP | 1 |
| Ansani, NT | 1 |
| Towers, AL | 1 |
| Schiller, LR | 1 |
| Celik, JB | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Sarkilar, G | 1 |
| Celik, C | 1 |
| Akyürek, C | 1 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 1 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| Konstam, MA | 1 |
| Choi, HK | 1 |
| Seeger, JD | 1 |
| Kuntz, KM | 1 |
| Degner, F | 1 |
| Lesaffre, E | 1 |
| Zeidler, H | 1 |
| Zhao, SZ | 1 |
| Wentworth, C | 1 |
| Burke, TA | 2 |
| Makuch, RW | 1 |
| Hanauer, LB | 1 |
| Jenkinson, ML | 1 |
| Rusche, JM | 1 |
| Dickman, A | 1 |
| Ellershaw, J | 1 |
| de Leval, X | 1 |
| Julémont, F | 1 |
| Benoit, V | 1 |
| Frederich, M | 1 |
| Pirotte, B | 1 |
| Dogné, JM | 1 |
| Fitzgerald, GA | 2 |
| Lugardon, S | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Chang, SY | 1 |
| Howden, CW | 1 |
| Simon, LS | 2 |
| Strand, V | 1 |
| Wolfe, MM | 1 |
| Goldstein, JL | 1 |
| Bello, AE | 1 |
| Spalding, W | 1 |
| Suh, S | 1 |
| Fort, JG | 1 |
| Hedner, T | 1 |
| Melander, A | 1 |
| Evensen, S | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Spiegel, BM | 1 |
| Chiou, CF | 1 |
| Ofman, JJ | 1 |
| Schaefer, M | 1 |
| DeLattre, M | 1 |
| Gao, X | 1 |
| Stephens, J | 1 |
| Botteman, M | 1 |
| Morreale, A | 1 |
| Fortun, PJ | 1 |
| Florentinus, SR | 1 |
| Heerdink, ER | 1 |
| de Boer, A | 1 |
| van Dijk, L | 1 |
| Braunstein, N | 1 |
| Polis, A | 1 |
| Waxman, HA | 1 |
| Gleason, PP | 1 |
| Williams, C | 1 |
| Hrdy, S | 1 |
| Hartwig, SC | 1 |
| Lassen, D | 1 |
| Kasliwal, R | 1 |
| Harris, S | 1 |
| Wilton, L | 1 |
| Frazier, KC | 1 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Drazen, JM | 1 |
| Ferraz, MB | 2 |
| Kvien, TK | 2 |
| Weaver, A | 1 |
| Smith, R | 1 |
| Schneeweiss, S | 1 |
| Solomon, DH | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Brookhart, MA | 1 |
| Depont, F | 1 |
| Fourrier, A | 1 |
| Merlière, Y | 1 |
| Droz, C | 1 |
| Amouretti, M | 1 |
| Bégaud, B | 1 |
| Bénichou, J | 1 |
| Moride, Y | 1 |
| Velo, GP | 1 |
| Sturkenboom, M | 1 |
| Blin, P | 1 |
| Moore, N | 1 |
| Singh, H | 1 |
| Sukel, MP | 1 |
| van der Linden, MW | 1 |
| Chen, C | 1 |
| Erkens, JA | 1 |
| Herings, RM | 1 |
| Smeeth, L | 1 |
| Persson, I | 1 |
| Parkinson, J | 1 |
| Freston, J | 1 |
| Whitney, E | 1 |
| MacConnachie, AM | 1 |
| Brooks, PM | 1 |
| Day, RO | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Buttgereit, F | 1 |
| Burmester, GR | 1 |
| Adelman, A | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Bannwarth, B | 1 |
| Patrono, C | 1 |
| Cleland, LG | 1 |
| James, MJ | 1 |
| Stamp, LK | 1 |
| Penglis, PS | 1 |
| Schoenfeld, P | 1 |
| Weaver, J | 1 |
| Bonnel, RA | 1 |
| Karwoski, CB | 1 |
| Brinker, AD | 1 |
| Beitz, J | 1 |
| Capriotti, T | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Hunt, RH | 1 |
| Barkun, AN | 1 |
| Baron, D | 1 |
| Bursey, FR | 1 |
| Marshall, JR | 1 |
| Morgan, DG | 1 |
| Paré, P | 1 |
| Thomson, AB | 1 |
| Whittaker, JS | 1 |
| Wolfe, F | 1 |
| Flowers, N | 1 |
| Arguelles, LM | 1 |
| Pettitt, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819] | Phase 2 | 150 participants | Interventional | 2001-11-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500] | Phase 4 | 24 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for rofecoxib and Cholera Infantum
| Article | Year |
|---|---|
The ADVANTAGE seeding trial: a review of internal documents.
Topics: Clinical Trials as Topic; Conflict of Interest; Cyclooxygenase 2 Inhibitors; Deception; Disclosure; | 2008 |
Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2003 |
NSAIDs: gastroprotection or selective COX-2 inhibitor?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gas | 2004 |
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Gastroint | 2004 |
[COX-2 inhibitors--one step forward and two steps back].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
Life after Vioxx: the clinical implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Tr | 2005 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygen | 2001 |
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2001 |
An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo | 2001 |
The new NSAIDs: cox-2 inhibitors.
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; | 2000 |
Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Dose | 2002 |
Considerations for the safe prescribing and use of COX-2-specific inhibitors.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2002 |
6 trials available for rofecoxib and Cholera Infantum
| Article | Year |
|---|---|
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Art | 2002 |
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygen | 2003 |
A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy.
Topics: Adult; Analgesia; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastrointestinal Diseases; Heartburn | 2003 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method | 2005 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2000 |
54 other studies available for rofecoxib and Cholera Infantum
| Article | Year |
|---|---|
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; D | 2008 |
Seeds of doubt--ADVANTAGE no one.
Topics: Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Gastrointestinal Diseases; Hum | 2008 |
Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celec | 2009 |
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 | 2011 |
Rofecoxib and clinically significant gastrointestinal events.
Topics: Cyclooxygenase 2 Inhibitors; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Lactones; Le | 2011 |
Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib.
Topics: Aged; Arthritis, Rheumatoid; British Columbia; Cohort Studies; Female; Gastrointestinal Diseases; Hu | 2012 |
Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Cyclooxygenase 2 I | 2012 |
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice.
Topics: Aging; Animals; Anxiety; Avoidance Learning; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2 | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 2002 |
Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Cost of | 2002 |
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Anti-Inflammat | 2003 |
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel | 2003 |
Adverse Drug Events Involving COX-2 Inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2003 |
Lower gastrointestinal complications of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Human | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Matters of the heart: assessing the cardiovascular safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2003 |
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Decision Support Techniques; Female; Gastroi | 2004 |
Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Bias; Gastrointest | 2004 |
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2004 |
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Celecoxib; Cyclooxygenase 2; Cyclo | 2004 |
A world without Vioxx: to COX-2 or not to COX-2?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact | 2004 |
[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Gastrointestinal Diseas | 2004 |
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cost-Benefit Analysis; Cyclooxy | 2005 |
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Comorbidity; Cyclooxyge | 2005 |
Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastroi | 2005 |
The lessons of Vioxx--drug safety and sales.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Drug Evaluation; Drug | 2005 |
Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cohort Studies; Cost-Benefit Analysis; Cyclooxygen | 2005 |
A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Product Surveilla | 2005 |
The lessons of Vioxx.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug In | 2005 |
Expression of concern reaffirmed.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones | 2006 |
Lapses at the new England journal of medicine.
Topics: Boston; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Gastrointestinal Disea | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxy | 2006 |
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxi | 2007 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Stud | 2008 |
Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?
Topics: Adult; Aged; Causality; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Databases, Fact | 2008 |
Rofecoxib and the risk of adverse upper gastrointestinal effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase Inhibitors; Gastrointestinal Dise | 2000 |
Rofecoxib and the risk of adverse upper gastrointestinal effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Human | 2000 |
Rofecoxib (Vioxx)--the first of a new generation of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cost of Illness; Cyclooxygenase Inhibitors; Drug | 2000 |
COX-2 inhibitors.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas | 2000 |
Is rofecoxib safer than naproxen?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Do | 2001 |
Selective COX-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2001 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; | 2001 |
GI events leading to death in association with celecoxib and rofecoxib.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Hum | 2001 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr
Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2; | 2002 |